Personalis, Inc.
Personalis, Inc. develops and sells advanced cancer genomic testing services for precision oncology and research applications. The company serves physicians, pharmaceutical and biopharmaceutical companies, diagnostics firms, universities, non-profits, and government customers from its CLIA-certified, CAP-accredited laboratory in Fremont, California.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaTumor-informed and other cancer tests used by physicians to guide care and monitor recurrence.
Testing and analytics for pharmaceutical oncology programs, translational research, and clinical trials.
Tumor profiling and diagnostic inputs sold to other businesses, including Natera-related services.
Large-scale sequencing services supporting population genetics and research initiatives.
Genomic tests and analytics sold to universities and non-profit research customers.
Asiakkaat
Personalis sells to both clinical and research customers, with a large share of revenue tied to a small number of pharmaceutical and healthcare partners. Its end markets include oncology drug developers, healthcare providers treating cancer patients, diagnostics companies, and public-sector or academic research programs.
They buy testing services and analytics for translational research, biomarker discovery, and clinical trials.
They order NeXT Personal Dx and related cancer tests to detect residual or recurrent disease and support therapy selection.
They purchase whole exome sequencing and tumor analysis services as inputs to their own diagnostic offerings.
They use whole genome sequencing and analytics for large-scale genetic research initiatives.
They buy genomic testing and analytics for academic and non-commercial research projects.
Strategia
Personalis is focused on expanding adoption of its NeXT Personal testing platform in clinical diagnostics while continuing to serve pharma and research customers. The company is also building clinical evidence, reimbursement support, and commercial partnerships to broaden access to its tests and reduce reliance on a small number of large accounts.
Clinical adoption can create a broader, more recurring customer base than project-based research work.
Coverage and published evidence support physician adoption and payer reimbursement.
Reducing dependence on a few large customers lowers volatility from trial timing and renewals.
Maantiede
Personalis derives most of its revenue in the United States, with smaller contributions from Europe, including the U.K., and a limited amount from the rest of the world, including Asia-Pacific. The company performs its laboratory work in Fremont, California, which anchors its operating footprint and regulatory compliance model.
Riskit
Personalis faces customer concentration risk because a small number of large accounts can drive a substantial share of revenue, and those customers' trial timing can be volatile. The business also depends on reimbursement, regulatory compliance, and data security, which are especially important in genomic testing because the company handles sensitive patient and genomic information.
- Customer concentrationVaikutus: KorkeaTodennäköisyys: Korkea
A few customers account for a large share of revenue, so renewals or project changes can materially affect results.
Kohdistuu - Clinical trial and project timingVaikutus: KorkeaTodennäköisyys: Korkea
Pharma and research revenue depends on the start, pace, and completion of external studies.
Kohdistuu: Pharma tests and services
- Cybersecurity and sensitive data protectionVaikutus: KorkeaTodennäköisyys: Matala
The company processes PHI, genomic data, and financial information, increasing breach and compliance risk.
Kohdistuu: Laboratory and third-party systems
- Sustained lossesVaikutus: KeskitasoTodennäköisyys: Korkea
The company has a history of losses and may need continued capital to support growth and operations.
Kohdistuu: Corporate liquidity and operating flexibility
- Reimbursement and coverage riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Clinical diagnostics depend on Medicare and private payer coverage for adoption and volume growth.
Kohdistuu: NeXT Personal Dx
Kirjanpito
Harkinnanvaraiset erätService contracts and clinical projects may be recognized at different points depending on delivery and contract terms.
Vaikutus: Can shift revenue between quarters and affect comparability
The company has significant operating lease commitments tied to its laboratory and headquarters.
Vaikutus: Affects right-of-use assets, lease liabilities, and expense timing
Warrants require fair value estimation and can create non-cash volatility.
Vaikutus: Can materially affect other income/expense and equity
Large customer balances and concentration require judgment on receivable recoverability.
Vaikutus: Can affect bad debt expense and working capital
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Tempus AI, Inc.
TEM · Services-Computer Programming, Data Processing, Etc.
Myriad Genetics, Inc
MYGN · In Vitro & In Vivo Diagnostic Substances
Myriad Genetics develops and commercializes molecular diagnostic tests that help clinicians assess disease risk, guide treatment selection, and support earlier…
Caris Life Sciences, Inc.
CAI · Services-Medical Laboratories
Caris Life Sciences is a Texas-based precision medicine company that uses molecular profiling, sequencing, and AI/ML analytics to help guide cancer diagnosis,…
NeoGenomics, Inc
NEO · Services-Testing Laboratories
NeoGenomics is a U.S.-based cancer diagnostics company that provides oncology testing and consultative pathology services to help clinicians identify, classify, and monitor cancer.
Nautilus Biotechnology, Inc.
NAUT · Laboratory Analytical Instruments
Veracyte, Inc
VCYT · Services-Medical Laboratories
Veracyte is a U.S.-based molecular diagnostics company that develops and commercializes genomic tests used in cancer and other disease areas.
Päivitetty: 24.9.2026